DEVELOPMENT OF IN VITRO METHODOLOGIES FOR INHIBITION OF PATHOGENIC BACTERIA BY POTENTIAL PROBIOTIC LACTOBACILLUS SPS; AN EVIDENCE FOR PRODUCTION OF ANTIMICROBIAL SUBSTANCES

Objective: Probiotic products consist of specific strains of live bacteria that have potentially favorable health effects. A number of studies provide evidence that milk products with probiotics may be beneficial for digestive health and may improve various digestive problems. The purpose of the present study was to investigate Lactobacillus species with potential activities isolated from different cheese samples of local market.Methods: A total 42 lactic acid bacteria strains were isolated, fourteen (14/42) best Lactobacillus isolates were selected by preliminary screening as potential probiotics with antimicrobial activity against pathogenic bacteria. All the fourteen Lactobacillus isolates were then characterized in vitro for their probiotic features and antimicrobial activities against pathogens.Results: The results noticed that all selected Lactobacillus isolates (CH3, CH4 and CH6) were screened and confirmed as Lactobacillus. The isolates were able to grow at different pH, NaCl and bile salts, also exhibited the best antimicrobial activities against pathogens. All the isolates were susceptible to antibiotics used and isolates were also revealed the noticeable aggregation and hydrophobicity studies.Conclusion: Selected Lactobacillus isolates were considered as ideal, effective probiotic bacteria. Thus, they could be examined further and contribute to preventing and controlling several infections associated with intestine and for human health benefits

Mechanism Involved in Biofilm Formation of <em>Enterococcus faecalis</em>

Enterococci are commensal bacteria in the gastrointestinal flora of animals and humans. These are an important global cause of nosocomial infections. A Biofilm formation constitutes an alternative lifestyle in which microorganisms adopt a multi-cellular behavior that facilitates and prolongs survival in diverse environmental niches. The species of enterococcus forms the biofilm on biotic and abiotic surfaces both in the environment and in the healthcare settings. The ability to form biofilms is among the prominent virulence properties of enterococcus. The present chapter highlights the mechanisms underlying in the biofilm formation by enterococcus species, which influences in causing development of the diseases

Shigellosis: A Conformity Review of the Microbiology, Pathogenesis and Epidemiology with Consequence for Prevention and Management issues

This paper has reviewed investigates that obtained from peer-reviewed literatures on Shigellosis. Foodborne diseases related to unhygienic food handling practices remain a major public health problem across the globe. The problem is rigorous in developing countries due to restrictions in securing most possible hygienic food handling practices. Data demonstrates that an estimated 75% of cases of diarrheal diseases are linked with the using up of foods contaminated with pathogenic microorganisms. Bacillary dysentery (Shigellosis) is a severe human disease caused by Shigellae. It is one of the major sources of diarrhoea in developing countries. The precise estimates of morbidity and mortality due to shigellosis are deficient, however it is widespread and has been reported to cause many outbreaks. The limited information available specifies Shigella to be a vital food borne pathogen in developing countries. In this Review, it is renowned that pathogenic Shigella is still public health problem. Therefore, a large amount of information has been generated concerning the host, pathogen and environmental factors that impact the pathogenesis of shigellosis at the cellular and molecular level and summarizes what is currently known about Shigella, elementing those features that contribute to pathogenesis and investigating the existing progress in the development of safe and low-cost multivalent vaccine. Thus this review is focused upon the epidemiology, disease burden and the therapeutic challenges of Shigellosis in developing countries perception

Aminoglycoside-Resistance Mechanisms in Multidrug-Resistant Staphylococcus aureus Clinical Isolates

Aminoglycoside resistance in six clinically isolated Staphylococcus aureus was evaluated. Genotypical examination revealed that three isolates (HLGR-10, HLGR-12, and MSSA-21) have aminoglycoside-modifying enzyme (AME) coding genes and another three (GRSA-2, GRSA-4, and GRSA-6) lacked these genes in their genome. Whereas isolates HLGR-10 and HLGR-14 possessed bifunctional AME coding gene aac(6′)-aph(2′′), and aph(3′)-III and showed high-level resistance to gentamycin and streptomycin, MSSA-21 possessed aph(3′)-III and exhibited low resistance to gentamycin, streptomycin, and kanamycin. The remaining three isolates (GRSA-2, GRSA-4, and GRSA-6) exhibited low resistance to all the aminoglycosides because they lack aminoglycoside-modifying enzyme coding genes in their genome. The transmission electron microscopy of the three isolates revealed changes in cell size, shape, and septa formation, supporting the view that the phenomenon of adaptive resistance is operative in these isolates

A Comparative In Vivo Scrutiny of Biosynthesized Copper and Zinc Oxide Nanoparticles by Intraperitoneal and Intravenous Administration Routes in Rats

Abstract During the present time, anti-microbial features of copper (Cu) and zinc oxide (ZnO) nanoparticles (NPs) are extensively used to combat the growth of pathogenic microbes. CuNPs and ZnONPs are recurrently used in cosmetics, medicine and food additives, and their potential for toxic impacts on human and ecosystem is of high concern. In this study, the fate and toxicity of 16- to 96-nm-ranged biosynthesized copper (Bio-CuNPs) and zinc oxide (Bio-ZnONPs) was assessed in male Wistar rats. In vivo exposures of the two nanoparticles are achieved through two different administration routes namely, intraperitoneal (i/p) and intravenous (i/v) injections. The three different concentrations, no observable adverse effect concentration (NOAEC), inhibitory concentration (IC50) and total lethal concentration (TLC), were appraised at the dose range of 6.1 to 19.82 μg/kg and 11.14 to 30.3 μg/kg for Bio-CuNPs and Bio-ZnONPs respectively, for both i/p and i/v routes on 14th and 28th day of observation. These dose ranges are considered based on the previous study of antibacterial dose on multidrug-resistant pathogenic bacteria. In this study, we investigated the toxic effect of Bio-CuNPs and Bio-ZnONPs on animal behaviour, animal mass, haematologic indices, organ indices and histopathology of liver, spleen, kidney and brain organs. We found that i/v and i/p administration of Bio-ZnONPs in three different doses did not cause mortality and body weight was slightly reduced up to second week of administration compared with the vehicle control group. At the dose ranges of 11–16 μg/kg (i/v) and 24–30 μg/kg (i/p), no significant changes were observed in the serum creatinine level as well as serum ALT, serum AST level and ALP level which were 40.7 mg/dl, 37.9 IU/L and 82.4 IU/L normal as compared to vehicle control on 14th and 28th day of observation. These findings are confirmed in liver, kidney and spleen indices and histopathology studies. Furthermore, liver and kidney injury occurred when the concentrations of Bio-CuNPs were at 9.5 μg/kg (IC50) and 11.7 μg/kg (TLC) for i/v route of administration. Similarly, increase in serum ALT (67.7 mg/dl), AST level (70 IU/L) and ALP (128 IU/L) was also observed. And the body weight was significantly lower than in the control group after 14th day, and there were statistically significant differences observed by this route; interestingly, the toxicity of Bio-CuNPs in serum is prolonged (up to 28th day). Effect of Bio-CuNPs through i/p route was considerably low as compare to the control. Results of the present study revealed that Bio-ZnONPs have no effect on kidney and liver function biomarkers (both i/v and i/p) as compared to Bio-CuNPs.Graphical abstractAs shown in graphical abstract (Fig. 1), our aim is to assess the toxicity of Bio-CuNPs and Bio-ZnONPs through in vivo protocol. According to Kahru and Dubourguier reviews, AgNPs, CuNPs and ZnONPs have been historically used as biocides, for preventing the growth of microorganisms and algae (Kahru and Dubourguier 2010). Therefore, as like pesticides, nanomaterials should be monitored for their toxic response toward non-target species, including humans and animals. To gain a better understanding whether the accidental release of metal-containing NPs may pose a threat to non-target species, assessing of toxic effect is indispensable.The ‘non-target organism’ is an organism which will be exposed to NPs after their incidental release into the environment

Bacteriophage therapy for Staphylococcus aureus bacteremia in streptozotocin-induced diabetic mice

The protective effect of bacteriophage was assessed against experimental Staphylococcus aureus lethal bacteremia in streptozotocin (STZ) induced-diabetic and non-diabetic mice. Intraperitoneal administrations of S. aureus (RCS21) of 2 x 10(8) CFU caused lethal bacteremia in both diabetic and non-diabetic mice. A single administration of a newly isolated lytic phage strain (GRCS) significantly protected diabetic and nondiabetic mice from lethal bacteremia (survival rate 90% and 100% for diabetic and non-diabetic bacteremic groups versus 0% for saline-treated groups). Comparison of phage therapy to oxacillin treatment showed a significant decrease in RCS21 of 5 and 3 log units in diabetic and nondiabetic bacteremic mice, respectively. The same protection efficiency of phage GRCS was attained even when the treatment was delayed up to 4 h in both diabetic and non-diabetic bacteremic mice. Inoculation of mice with a high dose (10(10) PFU) of phage GRCS alone produced no adverse effects attributable to the phage per se. These results suggest that phages could constitute valuable prophylaxis against S. aureus infections, especially in immunocompromised patients. (C) 2010 Institut Pasteur. Published by Elsevier Masson SAS. All rights reserved

Prevalence of multidrug-resistant Staphylococcus aureus in diabetics clinical samples

Antibiotic resistance in 40 Staphylococcus aureus clinical isolates from 110 diabetic patients (36%) was evaluated. Of these, 32 (80%) of the isolates showed multidrug-resistance to more than eight antibiotics and 35% isolates were found to be methicillin resistant S. aureus (MRSA). All 40 S. aureus strains (100%) screened from diabetic clinical specimens were resistant to penicillin, 63% to ampicillin, 55% to streptomycin, 50% to tetracycline and 50% to gentamicin. Where as low resistance rate was observed to ciprofloxacin (20%) and rifampicin (8%). In contrast, all (100%) S. aureus strains recorded susceptibility to teicoplanin, which was followed by vancomycin (95%). Genotypical examination revealed that 80% of the aminoglycoside resistant S. aureus (ARSA) have aminoglycoside modifying enzyme (AME) coding genes; however, 20% of ARSA which showed non-AME mediated (adaptive) aminoglycoside resistance lacked these genes in their genome. In contrast all MRSA isolates possessed mecA, femA genetic determinants in their genome

Additional file 2: of A Comparative In Vivo Scrutiny of Biosynthesized Copper and Zinc Oxide Nanoparticles by Intraperitoneal and Intravenous Administration Routes in Rats

Figure S3. TEM images of (A) Bio-CuNPs and (B) Bio-ZnONPs synthesized from Enterococcus faecalis [41]. (DOCX 901 kb

Additional file 1: of A Comparative In Vivo Scrutiny of Biosynthesized Copper and Zinc Oxide Nanoparticles by Intraperitoneal and Intravenous Administration Routes in Rats

Figure S1. FeSEM images of Bio-CuNPs from Enterococcus faecalis [32]. Figure S2: FeSEM images of Bio-ZnONPs from Enterococcus faecalis [37]. (DOCX 1058 kb

Cytotoxicity and Genotoxicity of Metal Oxide Nanoparticles in Human Pluripotent Stem Cell-Derived Fibroblasts

10.3390/coatings11010107Coatings1111-1